DOCSLIB.ORG

Thank You to Our 2018 Sponsors & Vendors!

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Thank You to Our 2018 Sponsors & Vendors! UNT Health Science Center Campus Gibson D. Lewis Library April 6, 2018 Thank you to our 2018 sponsors & vendors! Biomedical Solutions BioTek Instruments Charles River Envigo Eppendorf Laerdal Medical Merck & Co., Inc. MIDSCI MilliporeSigma Nexcelom Bioscience Office of Research Development PHC Corporation of North America Quest Diagnostics Thermo Fisher Scientific Quest has expanded its services so you can prescribe with confidence A growing crisis demands a growing response According to the US Centers for Disease Control and Prevention, opioids account for more than 60 percent of overdose deaths—nearly 100 each day. In Texas alone, there were 1,107 accidental opioid poisoning deaths in 2016.1 As the industry leader in drug testing, we're happy to offer your practice a broad scope of fast and efficient prescription drug monitoring to help protect your patients. Our PDM service features: • Fast turnaround time • Specimen format flexibility • medMATCH® specimen reporting with easy-to-read-and-interpret results • QuanumTM Electronic Health Record and ePrescribing For more information, ask a Quest rep at the booth or visit QuestPDM.com Quest proudly supports UNTHSC Research Appreciation Day 1. Amid opioid crisis, Texas subsidized drug distributor it's now investigating. The Texas Tribune. October 31, 2017. https://www.texastribune.org/2017/10/31/during-opioid- crisis-texas-subsidized-drug-company-its-now-investigati/. Accessed March 20, 2018. Table of Contents Posters ........................................................................................................................................1 Aging/Alzheimer’s Disease (Abstracts in the 100s) ............................................................................. 1 Biochemistry (Abstracts in the 200s) ................................................................................................. 12 Cancer (Abstracts in the 300s)........................................................................................................... 13 Cardiovascular (Abstracts in the 400s) .............................................................................................. 42 Cell Biology (Abstracts in the 500s) ................................................................................................... 62 Community Medicine (Abstracts in the 600s) ................................................................................... 69 Diabetes (Abstracts in the 700s) ....................................................................................................... 75 Education (Abstracts in the 800s)...................................................................................................... 85 Eye/Vision (Abstracts in the 900s) .................................................................................................... 91 General Medicine (Abstracts in the 1000s) ..................................................................................... 102 General Public Health (Abstracts in the 1100s) ............................................................................... 117 Health Disparities (Abstracts in the 1200s) ..................................................................................... 150 Immunology (Abstracts in the 1300s) ............................................................................................. 154 Integrative Physiology (Abstracts in the 1400s) .............................................................................. 156 Microbiology/Infectious Disease (Abstracts in the 1500s) .............................................................. 167 Molecular Genetics (Abstracts in the 1600s) ................................................................................... 172 Neuroscience (Abstracts in the 1700s) ............................................................................................ 174 Other (Abstracts in the 1800s) ........................................................................................................ 197 Pharmaceutical Sciences (Abstracts in the 1900s) ........................................................................... 230 Pharmacology (Abstracts in the 2000s) ........................................................................................... 234 Physical Medicine/OMM (Abstracts in the 2100s) .......................................................................... 238 Psychology (Abstracts in the 2200s) ................................................................................................ 243 Rehabilitative Sciences (Abstracts in the 2300s) ............................................................................. 251 Structural Anatomy (Abstracts in the 2400s) .................................................................................. 256 Women’s Health (Abstracts in the 2500s) ....................................................................................... 268 Oral Presentations .................................................................................................................. 281 Cancer (Abstracts in the 300s)......................................................................................................... 281 Cardiovascular (Abstracts in the 400s) ............................................................................................ 282 1 Immunology (Abstracts in the 1300s) ............................................................................................. 283 Integrative Physiology (Abstracts in the 1400s) .............................................................................. 285 Neuroscience (Abstracts in the 1700s) ............................................................................................ 286 Women’s Health (Abstracts in the 2500s) ....................................................................................... 289 2 Posters Aging/Alzheimer’s Disease (Abstracts in the 100s) 100 - Poster Classification: GSBS Student Presenter: Ann Abraham Daniel Department: Pharmacology and Neuroscience Authors: Ann Abraham Daniel, MSc (Med Sci); Talisa Silzer, BS; Jie Sun, BS; Nicole Phillips, PhD; Leigh Johnson, PhD; Sid O'Bryant, PhD; Robert Barber, PhD Epigenetic Risk Factors for Mild Cognitive Impairment, Alzheimer’s Disease and Metabolic Dysfunction in Mexican Americans Purpose: Alzheimer’s is the most common form of dementia and the 5th leading cause of death for those over 651. The population of Mexican American elders will grow seven-fold by 20502 with rates of mild cognitive decline (MCI) and Alzheimer’s disease (AD) increasing exponentially1. Mexican Americans are diagnosed with MCI and AD at younger ages than non-Hispanic whites3; 4. In addition, Mexican Americans who are diagnosed with AD are 1) less likely to carry the ApoEε4 genotype3-5., 2) suffer a greater burden of type 2 diabetes3; 6, 3) experience greater metabolic-related cognitive decline 7; 8 and 4) display a proteomic signature of AD that is heavily metabolic in nature4; 9, compared to non-Hispanic whites, whose proteomic signature for AD is dominated by inflammatory proteins. We hypothesized that differentially methylated regions of DNA (DMRs) are associated with age at onset of cognitive decline (MCI/AD) and metabolic dysfunction (metabolic syndrome/type 2 diabetes) in Mexican Americans. Methods: To test this hypothesis, we assayed genomic DNA methylation in samples from 14 female Mexican American participants enrolled in the Health and Aging Brain study in Latino Elders (HABLE). Participants were diagnosed with cognitive decline (n=4), metabolic dysfunction (n=3), both (n=4), or as a control (n=3). We isolated DNA from leukocytes and bisulfite treated the samples before running them on an Illumina MethylationEPIC chip in accordance with manufacturer’s recommendations to assay genomic DNA methylation. Results: Several interesting biological pathways showed significantly different methylation status between groups. When the participants were split on cognitive decline, DNA in the amyloid secretase, EGF receptor signaling, PDGF signaling, gonadotropin-releasing hormone receptor and Wnt signaling pathways were significantly hypermethylated in cases. In comparison, analyses based on metabolic dysfunction showed significant DNA hypomethylation in the beta1 and beta2 adrenergic receptor signaling pathways and hypomethylation of the gonadotropin releasing hormone receptor pathway in cases. Conclusions: The etiology of cognitive decline appears to differ between Mexican Americans and non- Hispanic whites. Future work will resolve how dementia risk differs between these and other ethnic groups. The knowledge gained from these studies will be critical to a better understanding of AD pathophysiology and the development of ethnicity-focused AD treatment options. 1 Acknowledgements: Research reported here was supported by the National Institute On Aging of the National Institutes of Health under Award Number R01AG054073. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The research team also thanks the local Fort Worth community and participants of the Health & Aging Brain Study. Sponsor: R01AG054073 IRB/IACUC#: 2012-083 2 101 – Poster Classification: Faculty / Staff (Not for Competition) Presenter: Tori Conger Department: Pharmacology and Neuroscience Authors: Tori Conger; Melissa Pierce, University of North Texas Health Science Center; James Hall, MD, University of North Texas Health
Load more

Recommended publications
  • 224 Subpart H—Hematology Kits and Packages
    § 864.7040 21 CFR Ch. I (4–1–02 Edition) Subpart H—Hematology Kits and the treatment of venous thrombosis or Packages pulmonary embolism by measuring the coagulation time of whole blood. § 864.7040 Adenosine triphosphate re- (b) Classification. Class II (perform- lease assay. ance standards). (a) Identification. An adenosine [45 FR 60611, Sept. 12, 1980] triphosphate release assay is a device that measures the release of adenosine § 864.7250 Erythropoietin assay. triphosphate (ATP) from platelets fol- (a) Identification. A erythropoietin lowing aggregation. This measurement assay is a device that measures the is made on platelet-rich plasma using a concentration of erythropoietin (an en- photometer and a luminescent firefly zyme that regulates the production of extract. Simultaneous measurements red blood cells) in serum or urine. This of platelet aggregation and ATP re- assay provides diagnostic information lease are used to evaluate platelet for the evaluation of erythrocytosis function disorders. (increased total red cell mass) and ane- (b) Classification. Class I (general mia. controls). (b) Classification. Class II. The special [45 FR 60609, Sept. 12, 1980] control for this device is FDA’s ‘‘Docu- ment for Special Controls for Erythro- § 864.7060 Antithrombin III assay. poietin Assay Premarket Notification (a) Identification. An antithrombin III (510(k)s).’’ assay is a device that is used to deter- [45 FR 60612, Sept. 12, 1980, as amended at 52 mine the plasma level of antithrombin FR 17733, May 11, 1987; 65 FR 17144, Mar. 31, III (a substance which acts with the 2000] anticoagulant heparin to prevent co- agulation). This determination is used § 864.7275 Euglobulin lysis time tests.
    [Show full text]
  • Partial Purification and Properties of a Plasminogen Activator from Human Erythrocytes
    Partial purification and properties of a plasminogen activator from human erythrocytes M. Semar, … , L. Skoza, A. J. Johnson J Clin Invest. 1969;48(10):1777-1785. https://doi.org/10.1172/JCI106144. Research Article The lysis time of euglobulin clots made with whole blood (plasma and red cells) was very much shorter than that of clots made with plasma alone, indicating a fibrinolytic component in red cells. A plasminogen activator was found in the stroma-free hemolysate, and proteolytic activity was found in the stromal fraction. The plasminogen activator, purified by using diethylaminoethyl-cellulose (DEAE-cellulose) in a batch procedure followed by column chromatography, was called erythrokinase (EK). On preliminary characterization, EK appears to activate human and bovine plasminogen in a manner similar to urokinase (UK), as determined by fibrinolytic and caseinolytic assays. The two enzymes can be separated by DEAE chromatography and acrylamide-gel electrophoresis, however, and they hydrolyze acetyl-L-lysine methyl ester and benzoyl arginine methyl ester at different rates. Find the latest version: https://jci.me/106144/pdf Partial Purification and Properties of a Plasminogen Activator from Human Erythrocytes M. SEMAR, L. SKOZA, and A. J. JOHNSON From the Department of Medicine, New York University Medical Center, and the American National Red Cross Research Laboratory, New York 10016 A B S T R A C T The lysis time of euglobulin clots made research on the fibrinolytic components contained in with whole blood (plasma and red cells) was very much the red cell, or on the possible physiologic role of red shorter than that of clots made with plasma alone, in- cells in thrombolysis.
    [Show full text]
  • Sudan University of Science and Technology College of Medical Laboratory Science Department of Hematology
    بسم هللا الرحمن الرحيم Sudan University of Science and Technology College of Medical Laboratory Science Department of Hematology D-dimer, PT and APTT levels among Renal Transplant Patients in Sudan مستويات الدي دايمر ,زمن البروثرومبين و زمن الثرموبوبﻻستين الجزئي المنشط وسط مرضي زراعة الكلى في السودان A thesis submitted for partial fulfillment of requirements of M.Sc. degree in Hematology Student Zubaida Mohamed Ahmed Abdalbagi, B.S.c 2013 Department of Hematology – Faculty of Medical Laboratory Sciences - Khartoum University Supervisor Dr. Hiba Badreldin Khalil, PhD Department of Hematology – Faculty of Medical Laboratory Sciences - Alneelain University 2019 بسم هللا الرحمن الرحيم قال تعالى : ْ اقْرَأْْبِاسْمِْْرَ بِكَْْاَّلِذيْخََلقَْ سورةْالعلقْ صدق هللا العظيمْ List of Contents Contents Page No I اﻵية List of Contents II List of Figures VI List of Tables VII List of Abbreviations VIII Dedication XI Acknowledgement XII Abstract / English Abstract XIII Arabic Abstract XIV / ملخص الدراسة Chapter One 1.1 Chronic Kidney Disease 1 1.1.1 Causes of Chronic Kidney Disease 6 1.1.2 Diagnosis 7 1.1.2.1 Differential diagnosis 7 1.1.3 Severity-Based Stages 7 1.1.4 Treatment of Chronic Kidney Disease 9 1.1.5 Prognosis of Chronic Kidney Disease 10 1.2 Kidney Transplantation 11 1.2.1 History of Kidney Transplantation 11 1.2.2 Indications 13 1.2.3.1Living donors 13 1.2.4 Deceased donors 61 1.2.5 Compatibility 18 1.2.6 Procedure 19 1.2.7 Post Operation 20 1.2.8 Complications 26 1.2.9 Prognosis 22 1.3 Homeostasis and Coagulation 23 1.3.1Nomenclature 24
    [Show full text]
  • Some Haematological Observations in Cardio- the Melrose Oxygenator
    Thorax: first published as 10.1136/thx.19.2.170 on 1 March 1964. Downloaded from Thorax (1964), 19, 170 Some haematological observations in cardio- pulmonary bypass at normothermia using the Melrose oxygenator R. A. CUMMING, S. H. DAVIES, K. KAMEL,' G. J. MACKENZIE, A. MASSON, AND J. D. WADE From the Cardiopulmonary Bypass Unit, The Royal Infirmary, Edinburgh Haemostasis is now generally accepted to be a FIG. 1. The clotting process. dynamic mechanism. In injury, haemostasis is Stage 1. Production of intrinsic thromboplastin or effected by a series of processes resulting finally in prothrombin activator the formation of a blood clot. This process involves Hageman factor (factor XII)-activated by contact capillary retraction whereby the severed vessel end with damaged vessel is narrowed; this is followed by the accretion of Plasma thromboplastin antecedent (factor XI) an occlusive platelet thrombus, and finally the Antihaemophilic factor (factor VIII) formation of a clot in the now static blood. Pro- Christmas factor (factor IX) Factor V (labile factor) gression of this process is probably limited and Stuart-Prower factor (factor X) controlled by the increased production of anti- Platelet factor 3 (co-factor 3) thrombin (and probably of other natural inhibi- Ca++ copyright. and the mechanism that tors), by fibrinolytic so Stage 2. Thrombin formation thrombus formation does not undergo retrograde Prothrombin Intrinsic Thrombin spread to involve the whole vascular tree. The fibrinolytic mechanism is also reparative and is thromboplastin active in the healing process. In normal health a Stage 3. Fibrin clot http://thorax.bmj.com/ fine balance between the haemostatic and fibrino- Fibrinogen Thrombin Fibrin lytic systems is said to maintain the integrity of the organism (Mole, 1948; Copley, 1954; Astrup, 1956 a and b; Jensen, 1956).
    [Show full text]
  • Hemostasis and Thrombosis
    PROCEDURES FOR HEMOSTASIS AND THROMBOSIS A Clinical Test Compendium PROCEDURES FOR HEMOSTASIS AND THROMBOSIS: A CLINICAL TEST COMPENDIUM Test No. Test Name Profile Includes Specimen Requirements Bleeding Profiles and Screening Tests 117199 aPTT Mixing Studies aPTT; aPTT 1:1 mix normal plasma (NP); aPTT 1:1 mix saline; aPTT 2 mL citrated plasma, frozen 1:1 mix, incubated; aPTT 1:1 mix NP, incubated control 116004 Abnormal Bleeding Profile PT; aPTT; thrombin time; platelet count 5 mL EDTA whole blood, one tube citrated whole blood (unopened), and 2 mL citrated plasma, frozen Minimum: 5 mL EDTA whole blood, one tube citrated whole blood (unopened), and 1 mL citrated plasma, frozen 503541 Bleeding Diathesis With Normal α2-Antiplasmin assay; euglobulin lysis time; factor VIII activity; 7 mL (1mL in each of 7 tubes) platelet-poor aPTT/PT Profile (Esoterix) factor VIII chromogenic; factor IX activity; factor XI activity; factor citrated plasma, frozen XIII activity; fibrinogen activity; PAI-1 activity with reflex to PAI-1 antigen and tPA; von Willebrand factor activity; von Willebrand factor antigen 336572 Menorrhagia Profile PT; aPTT; factor IX activity; factor VIII activity; factor XI activity; 3 mL citrated plasma, frozen von Willebrand factor activity; von Willebrand factor antigen Minimum: 2 mL citrated plasma, frozen 117866 Prolonged Protime Profile Factor II activity; factor V activity; factor VII activity; factor 3 mL citrated plasma, frozen X activity; fibrinogen activity; dilute prothrombin time Minimum: 2 mL citrated plasma, frozen
    [Show full text]
  • Changes in the Fibrinolytic System Components During Extracorporeal Circulation
    Thorax: first published as 10.1136/thx.21.3.215 on 1 May 1966. Downloaded from Thorax (1966), 21, 215. Changes in the fibrinolytic system components during extracorporeal circulation K. KAMEL1, S. H. DAVIES, AND R. A. CUMMING From the Haematology Department and Blood Transfusion Service, the Royal Infirmary, Edinburgh In 1954 Gibbon, after many years of experimental and Gerbode, 1956). Excessive fibrinolysis, how- work, achieved the first successful total body ever, has been the most commonly reported perfusion in a human patient using a form of disturbance and has sometimes given rise to cardiopulmonary bypass. A prime aim of all serious bleeding (Perkins, Osborn, and Gerbode, workers in this field since then has been to produce 1958). Activation of the fibrinolytic system has safe and adequate anticoagulation of the blood since been shown to be due to an in vivo factor, during such a procedure, and to reverse it swiftly which has sometimes apparently been dependent and safely at the end of the operation. Further- on the rate and duration of perfusion and on the more it seems advisable that there should be no pH changes occurring during this (von Kaulla (or at the most a minimal and insignificant) altera- and Swan, 1958), but the time of onset of tion in both the cellular and humoral elements maximum fibrinolytic activity has borne no of the blood due to this procedure. Although satis- relation to any specific cause. Reports on altera- factory results have been achieved, the methods tions of components of the fibrinolytic system used are still far from perfect.
    [Show full text]
  • SCHEDULE of FEES for the Laboratory Services Outpatient
    SCHEDULE OF FEES For the Laboratory Services Outpatient Payment Schedule Fee-For-Service Outpatient Laboratory Services in British Columbia Issued October 1, 2015 Revised as of June 1, 2020 SCHEDULE OF FEES For the Laboratory Services Outpatient PAYMENT SCHEDULE SCHEDULE OF FEES - Table of Contents Issued: October 1, 2015 Contents 1. HEMATOLOGY AND BLOOD BANK FEE ITEMS ........................................... 1-6 2. MICROBIOLOGY FEE ITEMS ........................................................................ 2-12 3. CHEMISTRY FEE ITEMS ............................................................................... 3-16 4. CYTOGENETICS FEE ITEMS ........................................................................ 4-29 5. VIROLOGY FEE ITEMS .................................................................................. 5-31 6. ANATOMIC PATHOLOGY FEE ITEMS .......................................................... 6-33 7. OTHER FEE ITEMS ........................................................................................ 7-34 1-2 Revised as of June 1, 2020 SCHEDULE OF FEES For the Laboratory Services Outpatient PAYMENT SCHEDULE Introduction to the Schedule of Fees Issued: October 1, 2015 Interpretation The Laboratory Services Schedule of Fees is issued under the authority of the Minister of Health and is effective as of October 1, 2015 and updated as necessary. The Schedule cannot be correctly interpreted without reference to the Laboratory Services General Preamble and to the notes contained within the respective sections.
    [Show full text]
  • The Effect of Quercetin-3-B-Rutinoside on Blood
    THE EFFECT OF QUERCETIN-3-S-RUTINOSIDE ON BLOOD COAGULATION AND THE DEVELOPMENT OF ATHEROSCLEROTIC LESIONS IN SWINE A Thesis Presented to The Faculty of the School of Sciences and Mathematics Morehead State University In Partial Fulfillment Of the Requirements for the Degree Master of Science in Biology by Milford C. Jarrells April, 1979 AP t-'·K;j/f,f-;,~,;.-, J37jlJ Accepted by the faculty of the School of Sciences and Mathematics, in partial fulfillment of the require­ ments for the Master of Science degree. Director o Master's Committee: ~~Ch,imn David J. S on ~ t'.. /979 ii ABSTRACT The effect of quercetin-3-S-rutinoside (rutin) was studied in domestic swine for changes in blood clotting times, fibrinolysis times, and platelet counts. The swine were divided into four experimental groups: (1) Control group (2) Swine which received daily rutin injections, (3) Swine which received daily rutin injections and underwent denudation of the abdominal aorta and (4) Swine which received only aortic denudation. Histological sections of the subjects were made 45 days after the denudation process. The sections were examined for the development of atherosclerotic lesions. Weekly blood samples were measured for partial thromboplastin times (PTT), euglobulin lysis times and platelet counts. It was found that rutin administration showed a decreased mean partial thromboplastin time and a prolonged euglobulin lysis time. Platelet counts remained unchanged from that of the control group. Histological examinations revealed.no early lesion development in the group which only received rutin. Slight removal of the endothelium was observed in subjects which had received the denudation procedures.
    [Show full text]
  • Euglobulin Lysis Times: an Update*
    ANNALS OF CLINICAL AND LABORATORY SCIENCE, Vol. 23, No. 5 Copyright © 1993, Institute for Clinical Science, Inc. Euglobulin Lysis Times: An Update* A. GLASSMAN, M.D., M. ABRAM, M.D., G. BAXTER, B.S., and A. SWETT Department of Laboratories, Vanderbilt University Medical Center, Nashville, TN 37232 ABSTRACT There are several clot lysis tests available to assess the presence of increased fibrinolysis in a clinical situation. These include whole blood, plasma, and “eugloblin” lysis tests. The euglobulin lysis test (ELT) is actually a modified plasma clot lysis time, which detects increased plas­ minogen activation and subsequent fibrinolysis. It does not detect the activity of antiplasmins. The purpose of this study was to determine ELT for a group of 25 ambulatory normals. There were 10 males and 15 females, ranging in age from 25 to 56 years. Citrate anticoagulated samples were obtained immediately after application of a tourniquet and 10 minutes after application of a sphygmomanometer inflated to midway between systolic and diastolic pressure. The citrated plasma was precipitated with cold ace­ tic acid. The precipitate contained fibrinogen, plasminogen, and plasmino­ gen activators, with fibrinolytic inhibitors theoretically removed. The pre­ cipitate was redissolved and the euglobulin solution was clotted with thrombin. The clotted sample was then incubated at 37°C and was observed at 10 minute intervals for clot lysis. Results: The reference range of onset of fibrinolysis was from 1.25 to 12 hours, with a mean of 3.78 hours ± 2.45 hours (1 S.D.). Venostasis (use of the sphygmomanometer) resulted in an ELT that was shorter than the non-venostasis specimens in 11 of 25 specimens.
    [Show full text]
  • FIBRINOLYSIS Paper Read During the Annual Meeting of the Royal College of Surgeons of England on 17Th December 1966 by G
    FIBRINOLYSIS Paper read during the Annual Meeting of the Royal College of Surgeons of England on 17th December 1966 by G. R. Fearnley, M.D., F.R.C.P. Consultant Physician, North Gloucestershire Area To MOST PEOPLE the term fibrinolytic therapy means the use of exogenous thrombolytic agents like streptokinase for the treatment of established thrombosis, either arterial or venous. This aspect, and it is only one aspect of fibrinolysis, has evoked little interest in this country, and one reason for this in respect of arterial thrombosis is the question: Once the blood supply has diminished sufficiently to produce infarction what good can be expected from dissolving the putative cause, and in any case how often can we be certain that a fibrinous thrombus is present? These objec- tions certainly apply to the thrombolytic treatment of cerebral and coronary infarctions; but have less cogency in the case of venous thrombosis. First, because the problem of infarction does not arise and, secondly, because, while the platelet may be of greater importance in arterial ob- struction, fibrin contributes significantly to the bulk of venous thrombi. Theoretically, then, thrombolytic therapy might be more relevant to venous than to arterial obstruction, but experience of the use of thrombolytic agents in venous thrombosis is both limited and in general uncontrolled. Nevertheless there is good evidence confirmed by phlebography that streptokinase can dissolve occlusive venous thrombi. Be this as it may, 1 propose to consider the possibility that endogenous fibrinolytic activity may play a part in the prevention of and perhaps recovery from venous thrombosis, and further to suggest that it may prove possible to enhance the body's own fibrinolytic activity by means of drugs as a prophylactic measure against venous thrombo-embolism.
    [Show full text]
  • Blood Work Free Download
    BLOOD WORK FREE DOWNLOAD Michael Connelly | 528 pages | 01 Oct 1998 | Little, Brown & Company | 9780446602624 | English | New York, United States How to test normal blood glucose levels A continuous glucose monitor uses a sensor to measure blood sugar levels. Doctors may also recommend an A1C test for people who have the following risk factors for prediabetes :. Terry McCaleb Jeff Daniels Cleveland Clinic. Detective John Waller. This does not mean that there is an expectation that something is wrong, most often Blood Work tests confirm that everything is going well after surgery. Upon completion of a blood test analysis, patients may receive a report with blood test abbreviations. Egyptian Journal of Chest Diseases and Tuberculosis. A doctor or nurse will collect a blood sample, usually from a vein in the arm or hand. Clinical biochemistry blood tests CPT — Detective Jaye Winston Paul Rodriguez Dietary glucose is the body's main source of energy. Mean platelet volume Von Willebrand factor Ristocetin-induced platelet aggregation Clotting factors Prothrombin time Partial thromboplastin time Thrombin time Activated clotting time Bleeding time animal enzyme Reptilase time Ecarin clotting time Dilute Russell's viper venom time Thromboelastography Thrombodynamics test Fibrinolysis Euglobulin lysis time D-dimer. The jazzy background score gives 'Blood Work' a classy touch. While it is helpful to have a general understanding of lab results and what they mean, the healthcare provider is ultimately responsible for interpreting the results and determining how to respond to Blood Work. If you want to know Blood Work the digits mean, check this out. Medline Plus. Updated University of Rochester Medical Center.
    [Show full text]
  • Evaluation of Fibrinolytic Efficacy of Averrhoa Bilimbi Linn. by Using Euglobulin Lysis Time Method
    Available online at www.ijmrhs.com cal R edi ese M ar of c l h a & n r H u e o a J l l t h International Journal of Medical Research & a S n ISSN No: 2319-5886 o c i t i Health Sciences, 2019, 8(9): 21-24 e a n n c r e e t s n I • • IJ M R H S Evaluation of Fibrinolytic Efficacy of Averrhoa Bilimbi Linn. by Using Euglobulin Lysis Time Method Feras M Almarshad* Department of Internal Medicine, College of Medicine, Shaqra University, Shaqra, Riyadh, Saudi Arabia *Corresponding e-mail: [email protected] ABSTRACT Background: An impaired fibrinolytic function had been reported in subjects suffering from venous thrombosis. The euglobulin clot lysis time is a test that reflects the overall fibrinolytic activity of plasma. Objective: To evaluate the fibrinolytic efficacy of ethanolic extract of Averrhoa bilimbi Linn. leaves by using Euglobulin lysis time method. Methods: Rats were divided into 3 groups. Each group was containing 6 rats. Group I: received vehicle (control) 0.9% saline solution; Group II: received 25 mg/kg ethanolic extract leaves of Averrhoa bilimbi Linn; Group III: received 50 mg/kg ethanolic extract leaves of Averrhoa bilimbi Linn. Blood (1.8 ml) was removed with a plastic syringe containing 0.2 ml 3.8% sodium citrate solution. The time interval between the addition of thrombin and the complete lysis of the clots was measured. The lysis time (min) was determined. Conclusion: We observed ethanolic extract of Averrhoa bilimbi Linn. leaves may increase the activators of the fibrinolysis.
    [Show full text]